Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and itwill greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.

Biotechnology

Pharmaceutical

Therapeutics

Cybrexa Therapeutics

Per Hellsund

Jaya Gautam

Laurie Kenvin

Vishwas Paralkar

Ranjit Bindra

Mike Needle

The Research and Development Team at Cybrexa Therapeutics is responsible for the discovery, design, and optimization of innovative small molecule DNA repair inhibitors. Comprising experts in chemistry and biology, this interdisciplinary team works collaboratively to advance the company's tumor-localizing peptide technology, aiming to enhance drug efficacy and safety in cancer treatment. Their efforts are critical in identifying and developing novel therapeutics that can be effectively combined with existing chemotherapy and radiotherapy options.

Research and Development Team

Leadership Team

Research and Development Team

About

Team members

Other teams at Cybrexa Therapeutics

Leadership Team